Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 13/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.43 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1981958 | 0.82 | KDM4E (0.55) | ARKDM4EUSP2ALDH1A1IMPDH2 | |
| SCHEMBL31503655 | 0.81 | ALDH1A1 (0.53) | ARKDM4EUSP2ALDH1A1IMPDH2 | |
| SCHEMBL2761994 | 0.80 | ALDH1A1 (0.59) | ARKDM4EUSP2ALDH1A1IMPDH2 | |
| SCHEMBL7980232 | 0.79 | KDM4E (0.46) | ARKDM4EUSP2ALDH1A1IMPDH2 | |
| SCHEMBL1039728 | 0.79 | AR (0.54) | ARKDM4EUSP2ALDH1A1IMPDH2 | |
| SCHEMBL4849000 | 0.78 | AR (0.47) | ARKDM4EUSP2ALDH1A1IMPDH2 | |
| SCHEMBL5468223 | 0.78 | AR (0.47) | ARKDM4EUSP2ALDH1A1IMPDH2 | |
| SCHEMBL31554560 | 0.78 | ALDH1A1 (0.55) | ARKDM4EUSP2ALDH1A1IMPDH2 | |
| SCHEMBL1505362 | 0.78 | MAPT (0.52) | MAPTNPSR1 | |
| SCHEMBL14720180 | 0.77 | ALDH1A1 (0.44) | ARKDM4EUSP2ALDH1A1IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | AR 1667/4885KDM4E 2017/4885USP2 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.